ClinicalTrials.gg

Program

ABBV-8736

A development code.

In AbbVie's pipeline, TREM1. Its studies are mostly in Crohn Disease, led by AbbVie.

Furthest: phase 2, since Aug 8, 20243 company-led studies, 1 open or runningNext primary completion: Jan 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie31 open or runningphase 2since Aug 8, 2024Aug 8, 2024Jan 2030phase 2 · NCT06548542
  • Named in AbbVie’s own pipeline as ABBV-8736, phase 2, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 8, 2024First study: phase 2 study in Crohn DiseaseFirst studyNCT06548542 · 590 planned · United States, Austria, Belgium and more
  2. Aug 19, 2025Phase 1 study in Healthy VolunteerNCT07141199 · 24 enrolled · United States
  3. Feb 10, 2026Phase 1 study in Healthy VolunteerNCT07413133 · 40 enrolled · United States

Ahead

  1. Jan 2030Primary completion: phase 2 study in Crohn DiseaseNCT06548542

TargetBeta

“TREM1”the company's pipeline, read by Claude · source

Other programs on TREM1

ProgramCompanyFurthest phaseStudies
BI 3032950Boehringer Ingelheimphase 23

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07413133Healthy Volunteer · United States1CompletedJun 19, 202640
NCT07141199Healthy Volunteer · United States1CompletedMar 23, 202624
NCT06548542Crohn Disease · United States, Austria, Belgium and more2RecruitingJan 2030590

How it is read

Names in the registry

  • “ABBV-8736”, 4 entries

Codes read as this program: ABBV8736.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.